This invention relates to crosslinked collagen and glycosaminoglycan materials, and to procedures for preparing such materials. It has been discovered that if collagen fibrils in an aqueous acidic solution are contacted with a crosslinking agent before being contacted with glycosaminoglycan, the materials produced have extremely low levels of thrombogenicity. Such materials are well suited for in-dwelling catheters, blood vessel grafts, and other devices that are in continuous contact with blood for long periods of time.

Patent
   4350629
Priority
Jul 29 1981
Filed
Jul 29 1981
Issued
Sep 21 1982
Expiry
Jul 29 2001
Assg.orig
Entity
Small
101
4
all paid
2. In the method of preparing crosslinked collagen-glycosaminoglycan composite material, the improvement of contacting collagen, which has been soaked in an aqueous acidic solution, with a crosslinking agent prior to contacting said collagen and said crosslinking agent with glycosaminoglycan.
1. A method for preparing a crosslinked collagen-glycosaminoglycan composite material, comprising:
a. soaking collagen in an aqueous acidic solution having a pH of below about six;
b. contacting said solution with a crosslinking agent; and
c. contacting a source of glycosaminoglycan with said solution.
3. A method of claims 1 or 2 wherein said aqueous acidic solution comprises acetic acid.
4. A method of claims 1 or 2 wherein said crosslinking agent comprises glutaraldehyde.
5. A method of claims 1 or 2 wherein said glycosaminoglycan is selected from the following group: chondroitin 6-sulfate, chondroitin 4-sulfate, heparin, heparin sulfate, keratan sulfate, dermatan sulfate, or chitin.
6. A crosslinked collagen-glycosaminoglycan composite material made by the methods of claims 1 or 2.
PAC GOVERNMENT SUPPORT

The invention described herein was supported in whole or in part by a grant from the National Institutes of Health.

This invention is in the fields of polymeric materials and biocompatible materials.

Composite materials made of collagen and glycosaminoglycan (GAG) have been shown to be highly useful for certain biochemical applications. For example, U.S. Pat. No. 4,060,081 (Yannas et al, 1977), the teachings of which are hereby incorporated by reference, discloses a multilayer membrane suitable for use as synthetic skin. The bottom layer, which is placed in contact with a woundbed, is a highly porous lattice comprising collagen that is crosslinked with GAG. This lattice provides a biophysical supporting structure in which cells can migrate and proliferate to heal the wound.

The typical procedures that have been used in the past to prepare collagen/GAG composite materials are described in U.S. application Ser. No. 30,183, filed on Apr. 16, 1979, now U.S. Pat. No. 4,280,954 and U.S. application Ser. No. 169,897, filed on July 17, 1980, now abandoned; the teachings of both of those applications are hereby incorporated by reference. Briefly, a preferred embodiment of those procedures comprises the following steps, in sequence:

1. Mechanically cutting and grinding a source of collagen into particulate form.

2. Soaking the particulate collagen in dilute acetic acid.

3. Homogenizing the solution in a blender.

4. Adding a source of glycosaminoglycan which has been ground into particulate form. Typically, enough GAG is added to the solution to comprise about 6% to about 12% by dry weight of the composite material. The collagen/GAG mixture normally precipitates out of the acidic solution and forms a fibrous dispersion.

5. The precipitate is homogenized in a blender.

6. The solution is contacted with a crosslinking agent such as glutaraldehyde.

7. The solution is quickly frozen in a shallow pan.

8. The frozen dispersion is subjected to a high degree of vacuum, causing the acidic fluid to evaporate while the spatial configuration of the partially crosslinked fibrils is maintained.

The composite material thus formed may be treated by additional procedures to remove all traces of glutaraldehyde and to increase the crosslinking density and strength of the composite material.

The resulting collagen/GAG composite material exhibits some degree of incompatibility with the blood. For example, a small amount of platelet aggregation may occur over a period of several months if blood is in continuous contact with this material. This degree of blood incompatibility might be tolerable if the collagen/GAG composite material is to be biodegraded over a relatively short period of time, as is the case when it is used as artificial skin. However, that level of blood incompatibility can lead to certain problems in the use of collagen/GAG composite materials for prosthetic devices which are not rapidly biodegraded and which are in continuous contact with blood. For example, collagen/GAG material, in a less porous form than the lattice used for synthetic skin, may be useful for in-dwelling catheters, blood vessel replacement material, and other prosthetic devices. For such uses, it is advantageous to utilize a composite material that does not cause platelet aggregation to any detectable extent.

This invention relates to a method of creating collagen and glycosaminoglycan (GAG) composite materials that have extremely high levels of blood compatibility. The Applicants have discovered that if an aqueous dispersion of collagen which has been swollen in acid is contacted with a crosslinking agent such as glutaraldehyde prior to adding GAG to the solution, the resulting composite material will cause extremely low or undetectable levels of blood platelet aggregation. The invention described herein also relates to composite materials formed by this method. These materials are highly useful for prosthetic devices that will remain in contact with blood for very long periods of time, including indwelling catheters, blood vessel grafts, and other prosthetic devices that are not rapidly biodegraded.

In one preferred embodiment of this invention, a source of collagen is ground into particulate form and contacted with dilute acetic acid. The acidic solution is stirred to ensure thorough contact of all collagen with acid. The collagen is subsequently allowed to swell for 72 hours to remove all native banding.

After swelling, a crosslinking agent comprising glutaraldehyde is added in the form of an aqueous solution. The final glutaraldehyde concentration is approximately equal to 0.5% weight/volume. The solution normally is stirred while the glutaraldehyde is being added.

Following the addition of glutaraldehyde, a solution of chondroitin 6-sulfate (which is a glycosaminoglycan) is added to the acidic collagen solution. The chondroitin 6-sulfate is first dissolved in dilute acetic acid, and added dropwise to the collagen solution while it is being stirred.

The resulting dispersion may be treated in any of several ways. In order to create a prosthetic device, it may be frozen and lyophilized. In order to test its blood compatibility properties, it may be filtered, air-dried, ground into particulate form, and dispersed in physiological saline solution.

PAC Example 1: Preparation of Collagen/GAG Material

Collagen from bovine hide, prepared by the methods described by M. Komanowsky et al, J. Amer. Leather Chemists Assn. 69: No. 9, p. 410-422 (1974), was donated by H. I. Sinnamon of the U.S. Dept. of Agriculture. 0.55 g. of freeze-dried collagen was ground in a Wiley mill (A. H. Thomas Co., Phila. PA) to a 60 mesh particle size. It was added to 200 ml of 0.05 M aqueous acetic acid. This solution was stirred for 60 minutes in an ice-jacketed blender (Eberbach Corp., Ann Arbor, MI) on a 2-speed power unit (Waring Co., Hartford, CT) set on high speed with the line voltage reduced to 50% of 120 volts. Following this blending step, the solution was placed in a tightly closed glass jar and the collagen was allowed to swell for 72 hours at 4°C

A solution of 25% glutaraldehyde ("Baker-analyzed" reagent grade, J. T. Baker Co., Phila. PA) in distilled water was prepared. A sufficient quantity of this solution was added to the acidic collagen solution to comprise 0.5% glutaraldehyde volume per volume. The glutaraldehyde solution was added while the dispersion was blended for one hour in an overhead blender (Hamilton Beach Div. of Scovill, Washington, N.C.) set on the low speed with the line voltage reduced to 60% of 120 volts.

0.0578 g chondroitin 6-sulfate was dissolved in 10 ml of 0.05 M acetic acid. This solution was added to 175 ml of the glutaraldehyde-treated collagen dispersion. The addition was performed over a period of 5 minutes while the dispersion was being blended in the overhead blender.

Shortly thereafter, the dispersion was filtered in a Buechner funnel. This filtering step was completed in about 20 minutes. The resulting wet membrane was then air-dried and milled to a 60 mesh particle size. It was dispersed in physiological saline solution (0.15 M NaCl, pH7) prior to being contacted with blood platelets.

Two other dispersions of collagen/GAG were prepared as described above, with the following changes. In one specimen, the glutaraldehyde crosslinking step was omitted. In the other specimen, chondroitin 6-sulfate was added to the collagen dispersion prior to the addition of glutaraldehyde.

Blood plasma that was rich in platelet content was obtained from healthy, drug-free human donors (Beth Israel Hospital, Boston, MA) by using the procedures described in F. H. Silver et al, "Glycosaminoglycan Inhibition of Collagen-Induced Platelet Aggregation," Thrombosis Research 13: 267-277 (1978). Platelet clotting was measured with an aggregometer (Chrono-Log Corporation Model 300, Broomall, PA).

When platelet-rich plasma was contacted with the collagen/GAG dispersion that had not been contacted with glutaraldehyde, the collagen/GAG material caused rapid formation of a platelet clot. When the platelet-rich plasma was contacted with the collagen/GAG that had been contacted with glutaraldehyde subsequent to the addition of chondroitin 6-sulfate, a small amount of platelet aggregation occurred if the dispersion had been stored for a period of several months in physiological saline prior to being contacted with platelet-rich plasma. By contrast, when the glutaraldehyde crosslinking step preceded the addition of chondroitin 6-sulfate, as described in Example 1, no platelet aggregation could be detected, regardless of whether the dispersion was stored in physiological saline for up to one month prior to being contacted with platelet-rich plasma.

This invention has industrial applicability in the preparation of collagen prosthetic devices that have very high levels of blood compatibility.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

Yannas, Ioannis V., Forbes, Martin J.

Patent Priority Assignee Title
10016534, Nov 17 2008 PETVIVO HOLDINGS, INC Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
10022214, Dec 20 2011 LifeCell Corporation Sheet tissue products
10077420, Dec 02 2014 OCUGEN, INC Cell and tissue culture container
10327884, Jan 24 2012 LifeCell Corporation Elongated tissue matrices
10722339, Dec 20 2011 LifeCell Corporation Flowable tissue products
10842610, Jul 03 2007 OCUGEN, INC Method for use of a double-structured tissue implant for treatment of tissue defects
10953044, Apr 24 2012 LifeCell Corporation Functionalized tissue matrices
11555172, Dec 02 2014 OCUGEN, INC Cell and tissue culture container
11890371, Dec 26 2007 PETVIVO HOLDINGS, INC Biocompatible protein-based particles and methods thereof
4448718, Sep 13 1983 Massachusetts Institute of Technology; MASSACHUSETTS INSTITUTE OF TECHNOLOGY, 77 MASSACHUSETTS AVE , CAMBRIDGE, MA 02139 A MA CORP Method for the preparation of collagen-glycosaminoglycan composite materials
4451397, Nov 30 1981 CENTRE TECHNIQUE CUIR, CHAUSSURE, MAROQUINERIE Method of preparing collagen products
4585754, Jan 09 1984 FLS ACQUISITION CORP , D B A BIORELEASE TECHNOLOGIES Stabilization of proteins and peptides by chemical binding with chondroitin
4703108, Mar 27 1984 University of Medicine & Dentistry of New Jersey Biodegradable matrix and methods for producing same
4745098, Feb 24 1984 The Regents of the University of California; University of California Compositions and method for improving wound healing
4751935, Apr 09 1987 LEE PHARMACEUTICALS, 1444 SANTA ANITA AVE , SOUTH EL MONTE, CA 91733, A CORP OF CA Artificial fingernail
4760131, Apr 23 1986 CELTRIX PHARMACEUTICALS, INC Wound-healing composition
4808570, Feb 24 1984 University of California; REGENTS OF THE UNIVERSITY OF CALIFORNIA THE Compositions and method for improving wound healing
4837285, Mar 27 1984 MediMatrix Collagen matrix beads for soft tissue repair
4880429, Jul 20 1987 REGEN CORPORATION, Prosthetic meniscus
4947840, Aug 21 1987 MASSACHUSETTS INSTITUTE OF TECHNOLOGY, 77 MASSACHUSETTS AVENUE, CAMBRIDGE, MASSACHUSETTS 02139, A CORP OF MA Biodegradable templates for the regeneration of tissues
5007934, Jul 20 1987 ReGen Corporation Prosthetic meniscus
5008116, Nov 14 1988 Biomaterials Corporation Immunostimulatory microsphere
5028597, Apr 07 1986 DAIICHI PHARMACEUTICAL CO , LTD Antithrombogenic materials
5071436, Jul 30 1985 BASF Beauty Care Solutions France SAS Substitute bony matrix products promoting osteogenesis
5108438, Jul 20 1987 ReGen Corporation Prosthetic intervertebral disc
5116374, Jul 20 1987 ReGen Corporation Prosthetic meniscus
5116824, May 02 1985 Katakura Chikkarin Co., Ltd.; Koken Co., Ltd. Biomaterial comprising a composite material of a chitosan derivative and collagen derivative
5158574, Jul 20 1987 ReGen Corporation Prosthetic meniscus
5169631, Oct 10 1989 C S ; LABORATOIRES C S Topical antimicrobial composition and uses
5209776, Jul 27 1990 TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF YORK, THE Tissue bonding and sealing composition and method of using the same
5258043, Jul 20 1987 ReGen Corporation Method for making a prosthetic intervertebral disc
5263984, Jul 20 1987 REGEN BIOLOGICS, INC Prosthetic ligaments
5273900, Apr 28 1987 The Regents of the University of California Method and apparatus for preparing composite skin replacement
5282859, Apr 24 1990 ORTEC INTERNATIONAL, INC Composite living skin equivalents
5306311, Jul 20 1987 ReGen Corporation Prosthetic articular cartilage
5605938, May 31 1991 TRIAD, LLC Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
5624463, Mar 02 1989 REGEN BIOLOGICS, INC Prosthetic articular cartilage
5629191, Jan 03 1985 INTEGRA LIFESCIENCES CORPORATION Method of making a porous matrix particle
5645591, May 29 1990 MARIEL THERAPEUTICS, INC Synthetic bone matrix
5681353, Jul 20 1987 REGEN BIOLOGICS, INC Meniscal augmentation device
5705177, May 31 1991 TRIAD, LLC Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
5705178, Dec 08 1993 TRIAD, LLC Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
5714582, Mar 17 1995 BIOSCIENCE CONSULTANTS, L L C Invertebrate type V telopeptide collagen, methods of making, and use thereof
5731298, Jan 03 1992 Method for the treatment of scars and keloids
5735902, Jul 20 1987 REGEN BIOLOGICS, INC Hand implant device
5735903, Jul 20 1987 Ivy Sports Medicine, LLC Meniscal augmentation device
5814328, Jan 13 1997 Preparation of collagen using papain and a reducing agent
5916557, Nov 12 1993 TARRANT, LAURENCE J B ; TOKUMO, TOSHIMASA Methods of repairing connective tissues
5994325, May 31 1991 TRIAD, LLC Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
6020326, May 31 1991 TRIAD, LLC Method for inhibition of bone growth by anionic polymers
6042610, Jul 20 1987 REGEN BIOLOGICS, INC Meniscal augmentation device
6083930, May 31 1991 TRIAD, LLC Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
6127348, Jun 06 1995 TRIAD, LLC Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
6468308, May 29 1990 Stryker Corporation Synthetic bone matrix
6548077, Jan 13 1997 Purifying type I collagen using two papain treatments and reducing and delipidation agents
6605117, May 29 1990 Stryker Corporation Synthetic bone matrix
6916910, Mar 17 1995 Bioscience Consultants Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof
6933326, Jun 19 1998 LifeCell Corporation Particulate acellular tissue matrix
6982298, Jan 10 2003 The Cleveland Clinic Foundation; CLEVELAND CLINIC FOUNDATION, THE Hydroxyphenyl cross-linked macromolecular network and applications thereof
7309359, Aug 21 2003 Warsaw Orthopedic, Inc Allogenic/xenogenic implants and methods for augmenting or repairing intervertebral discs
7314860, Nov 25 1997 Jenny Ja Antti Wilhurin Rahasto Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
7358284, Jun 19 1998 LifeCell Corporation Particulate acellular tissue matrix
7368502, Jan 08 2004 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
7465766, Jan 08 2004 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
7504113, Nov 25 1997 Jenny Ja Antti Wihurin Rahasto Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
7713303, Sep 18 2002 Warsaw Orthopedic, Inc Collagen-based materials and methods for augmenting intervertebral discs
7731981, Nov 15 2002 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
7744651, Sep 18 2002 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
7887593, Sep 18 2002 Warsaw Orthopedic, Inc Method of implanting natural tissue within the vertebral disc nucleus space using a drawstring
8021350, Jan 10 2003 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
8070827, Jul 03 2007 OCUGEN, INC Method for use of a double-structured tissue implant for treatment of tissue defects
8080260, Feb 13 2008 The Cleveland Clinic Foundation Molecular enhancement of extracellular matrix and methods of use
8118779, Jun 30 2006 Warsaw Orthopedic, Inc Collagen delivery device
8137688, Jan 10 2003 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
8138265, Jan 10 2003 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
8153591, Aug 26 2004 PETVIVO HOLDINGS, INC Protein biomaterials and biocoacervates and methods of making and using thereof
8207262, Jan 10 2003 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
8399619, Jun 30 2006 Warsaw Orthopedic, Inc Injectable collagen material
8410180, Apr 30 2008 The Cleveland Clinic Foundation Methods to treat urinary incontinence
8415324, Nov 25 1997 Jenny Ja Antti Wihurin Rahasto Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
8465537, Jun 17 2003 PETVIVO HOLDINGS, INC Encapsulated or coated stent systems
8623393, Apr 29 2002 PETVIVO HOLDINGS, INC Biomatrix structural containment and fixation systems and methods of use thereof
8685107, Jul 03 2007 OCUGEN, INC Double-structured tissue implant and a method for preparation and use thereof
8871267, Sep 25 1998 PETVIVO HOLDINGS, INC Protein matrix materials, devices and methods of making and using thereof
8921109, Sep 19 2005 OCUGEN, INC Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
9011543, Aug 21 2003 Warsaw Orthopedic, Inc. Methods for augmenting or repairing intervertebral discs with allogenic/xenogenic implants
9107937, Aug 26 2003 PETVIVO HOLDINGS, INC Wound treatments with crosslinked protein amorphous biomaterials
9149562, Jul 03 2007 OCUGEN, INC Method for use of a double-structured tissue implant for treatment of tissue defects
9271821, Jan 24 2012 LifeCell Corporation Elongated tissue matrices
9393347, Jul 03 2007 OCUGEN, INC Double-structured tissue implant and a method for preparation and use thereof
9421304, Jul 03 2007 OCUGEN, INC Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant
9532863, Dec 20 2011 LifeCell Corporation Sheet tissue products
9549805, Dec 20 2011 LifeCell Corporation Flowable tissue products
9592125, Dec 22 2006 LABORATOIRE MEDIDOM S A In situ system for intra-articular chondral and osseous tissue repair
9687590, Jul 03 2007 OCUGEN, INC Double-structured tissue implant and a method for preparation and use thereof
9701940, Sep 19 2005 OCUGEN, INC Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
9913705, Dec 20 2011 LifeCell Corporation Flowable tissue products
9993326, Jul 03 2007 OCUGEN, INC Method for use of a double-structured tissue implant for treatment of tissue defects
9999637, Apr 24 2012 LifeCell Corporation Functionalized tissue matrices
9999705, Aug 26 2003 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
RE35399, Apr 24 1990 ORCEL LLC Composite living skin equivalents
Patent Priority Assignee Title
3527225,
4060081, Jul 15 1975 Massachusetts Institute of Technology Multilayer membrane useful as synthetic skin
4233360, Nov 22 1975 COHESION TECHNOLOGIES, INC Non-antigenic collagen and articles of manufacture
4280954, Jul 15 1975 Massachusetts Institute of Technology Crosslinked collagen-mucopolysaccharide composite materials
///
Executed onAssignorAssigneeConveyanceFrameReelDoc
Jul 22 1981YANNAS, IOANNIS V Massachusetts Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST 0039130354 pdf
Jul 28 1981FORBES, MARTIN J Massachusetts Institute of TechnologyASSIGNMENT OF ASSIGNORS INTEREST 0039130354 pdf
Jul 29 1981Massachusetts Institute of Technology(assignment on the face of the patent)
Date Maintenance Fee Events
Feb 28 1986M170: Payment of Maintenance Fee, 4th Year, PL 96-517.
Mar 19 1990M171: Payment of Maintenance Fee, 8th Year, PL 96-517.
Mar 30 1990ASPN: Payor Number Assigned.
Mar 24 1994M285: Payment of Maintenance Fee, 12th Yr, Small Entity.
Apr 05 1994SM02: Pat Holder Claims Small Entity Status - Small Business.


Date Maintenance Schedule
Sep 21 19854 years fee payment window open
Mar 21 19866 months grace period start (w surcharge)
Sep 21 1986patent expiry (for year 4)
Sep 21 19882 years to revive unintentionally abandoned end. (for year 4)
Sep 21 19898 years fee payment window open
Mar 21 19906 months grace period start (w surcharge)
Sep 21 1990patent expiry (for year 8)
Sep 21 19922 years to revive unintentionally abandoned end. (for year 8)
Sep 21 199312 years fee payment window open
Mar 21 19946 months grace period start (w surcharge)
Sep 21 1994patent expiry (for year 12)
Sep 21 19962 years to revive unintentionally abandoned end. (for year 12)